Oliva Therapeutics Introduces Amerithroid™ for Hypothyroidism

In July 2026, Oliva Therapeutics announced the launch of Amerithroid™, offering a new American-made thyroid option, a naturally derived desiccated thyroid extract (DTE) that provides both levothyroxine (T4) and liothyronine (T3) for patients with hypothyroidism.

A New Choice in Hypothyroidism Treatment

Amerithroid is a new American-made, naturally derived T3/T4 thyroid option built on a strong history of domestic manufacturing. It shares its roots with Jerome Stevens Pharmaceuticals, the maker of Unithroid®, which was the first FDA-approved levothyroxine tablet. According to Oliva Therapeutics CEO Daniel Akeson, this launch of Amerithroid™ is years in the making and builds on my family’s deep connection to patients with hypothyroidism and our commitment to quality U.S. manufacturing of pharmaceutical products. This medicine brings a trusted, domestic choice for people who need hormone replacement care.

The launch follows the successful relaunch of Thyquidity®, a liquid levothyroxine for those who have difficulty swallowing tablets, including children. Michael Turnamian, COO of Oliva Therapeutics, also remarked that this is a key step in expanding their endocrine-focused portfolio while engaging prescribers to explore options for their patients.

Amerithroid is a reliable, naturally derived T3/T4 hypothyroidism treatment made by JSP, as the creator of Unithroid® with U.S. manufacturing excellence. Daniel Akeson, CEO of Oliva Therapeutics, LLC, stated that this launch brings a trusted legacy of patient care and a strong commitment to high quality.

Impact on the Healthcare Industry

This Amerithroid™ launch positively impacts the healthcare industry by offering a domestically sourced natural desiccated thyroid (DTE) option and addressing supply chain fragilities, along with pursuing rigorous regulatory alignment by addressing offshore manufacturing dependencies and regulatory uncertainty surrounding natural hormone therapies.

This medication enhances domestic supply security by depending entirely on U.S. manufacturing by Jerome Stevens Pharmaceuticals to lower foreign supply chain risks. It also expands clinical options through a natural dual T3 and T4 profile in precise strengths, while ensuring standardization with strict manufacturing consistency. This product also supports healthcare by offering high-level ingredient traceability modeled after FDA standards. It also helps doctors treat hypothyroidism safely with reliable, consistent doses made entirely within the U.S.

This further addresses challenges in the industry by solving chronic supply vulnerabilities, clearing regulatory gray areas, and preventing product substitution risks through domestic production, stringent compliance, and consistent potency. Exclusive U.S. manufacturing stops overseas shipping delays and active ingredient shortages. Formal regulatory paths, including the Biologics License Application, clear up old animal extract rules. Clear prescribing rules also give doctors and sensitive patients steady and reliable medication choices.

Impact of the Hormone Replacement Therapy Industry

The global hormone replacement therapy market size is valued at USD 39.64 billion in 2025 and is predicted to increase from USD 42.02 billion in 2026 to approximately USD 70.63 billion by 2035, expanding at a CAGR of 5.95% from 2026 to 2035.

According to Precedence Research, this impacts the thyroid hormone replacement industry by introducing a domestic, naturally derived T3/T4 desiccated thyroid extract (DTE) that addresses industry-wide supply chain, traceability, and standardization limitations.

This medication strengthens domestic security by being sourced and manufactured entirely in the U.S. by Jerome Stevens Pharmaceuticals, which lowers foreign reliance and stabilizes the supply. It provides clinicians and patients with a standardized natural T3/T4 combination alternative to synthetic monotherapies.

This launch further overcomes industry limitations by tackling supply chain fragility through exclusive U.S. manufacturing, closing quality and traceability gaps through stringent U.S. Pharmacopeia batch testing on final tablets, and stopping counterfeit concerns using a distinctive Oliva leaf logo, allowing direct visual verification by patients and pharmacists.

About Oliva Therapeutics

Oliva Therapeutics is a U.S. specialty healthcare company focusing on endocrine and cardiovascular medicines, providing product commercialization services and dedicated pharmaceutical distribution. Headquartered in New Jersey and was founded in 2022 by Daniel Akeson and Michael Turnamian. Beyond product manufacturing, Oliva offers comprehensive commercialization services and utilizes national distributors like Cardinal Health, Cencora, and McKesson for logistical support. Through strategic global partnerships, the firm manages product pipelines for North American markets.

Oliva Therapeutics aims to provide clarity and simplicity in healthcare through a portfolio of high-quality products, including the US-manufactured Amerithroid™ and Thyquidity® thyroid treatments, alongside Digoxin tablets. The company operates with a focus on integrity, family-rooted values, and secure domestic supply chains.